the aid library

LIST OPTIONS

Filter

159

Sort by:

Direction:

Download (404)

View PDF (895)

Philippines: 2014 Global AIDS Response Progress Reporting

UNAIDS (2014) C1

Download (89)

View PDF (151)

The impact of transition from Global Fund support to govermental funding on the sustainability of Harm Reduction programs

G. Shaw Eurasian Harm Reduction Network; ICASO (2016) C2

A case study from Albania June 2016 EHRN is grateful to all who contributed to this document, especially (in alphabetical order): Alena Alba, Program Officer, Eastern Europe and Central Asia Team, Asia, Europe, Latin America and the Caribbean Department, The Global Fund to Fight AIDS, Tuberc... more

Download (991)

View PDF (1601)

Job AIDS for ART providers in Kenya

Dr. Martin Sirengo Ministry of Health (2015) CC

Download (515)

View PDF (887)

FY 2015 Tanzania Country Operational Plan

PEPFAR (2016) C1

Download (328)

View PDF (912)

Extending Prevention of Mother-to-Child Transmission through Postpartum Family Planning in Lesotho

Frontiers in Reproductive Health, Family Health Department, Ministry of Health and Social Welfare, Kingdom of Lesotho (2008) C2

Download (408)

View PDF (3684)

AIDSFree Project Monitoring and Evaluation Indicators Progress Report October 1, 2015 - March 31, 2016

AIDSFree Project (2016) C1

The long-term goal of AIDSFree is to improve the quality and effectiveness of high-impact, evidence-informed HIV and AIDS interventions. This semiannual performance report (SAPR) summarizes AIDSFree's achievements for the period October 1, 2015–March 31, 2016

Download (524)

View PDF (846)

Nigeria Quality of Care: Technical Report June 2015

National Agency for the Control of AIDS (NACA), Abuja Nigeria (2015) C1

Download (93)

View PDF (994)

The twin epidemics: Prevalence of TB/HIV co- infection and its associated factors in Ethiopia; A systematic review and meta-analysis

B. Tesfaye; A. Alebel; A. Gebrie; et al. PLOS One (2018) CC

PLOS ONE | https://doi.org/10.1371/journal.pone.0203986 October 3, 2018

Download (452)

View PDF (1207)

The Uganda National Tuberculosis Prevalence Survey, 2014-2015 Survey Report

Ministry of Health, Republic of Uganda (2017) C2

Download (2150)

View PDF (2074)

Guidelines for Health Staff Caring for Gender-based Violence Survivors: Including Protocol for Clinical Management of Rape [EN]

UN High Commissioner for Refugees, Protection Cluster, Health Cluster (2016) C1

Gender-based violence, including rape is a problem throughout the world, occurring in every society, country and region. Refugees and internally displaced people are particularly at risk of this violation during every phase of an emergency situation. The systematic use of sexual violence as a method... more

Download (434)

View PDF (723)

The Balanced Counseling Strategy Plus. A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings. Trainer's Guide, 3rd ed.

Population Council (2015) C1

Download (218)

View PDF (375)

Rwanda: Six Year Strategic Plan for The Epidemic Infectious Diseases Division 2012-2018

Ministry of Health Rwanda, Biomedical Center Institute of HIVAIDS, Disease Prevention and Control & Epidemic Infectious Diseases Division (2012) C2

Final Draft narrative December 6, 2012 - This strategic plan, developed through the joint collaboration of all stakeholders in the different sectors is aimed at harnessing and bringing together all the stakeholders who have a role in the prevention, detection and management of epidemic and infectiou... more

Download (1470)

View PDF (2029)

Recommendations for pharmacy management and the dispensing ofAnti-RetroviralMedicines in Resource-limited settings

FIP Working Group on Pharmacists and HIV-AIDS InternationalPharmaceuticalFederation (2008) CC

Download (298)

View PDF (384)

The Balanced Counseling Strategy Plus. A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings. User's Guide, 3rd ed.

Population Council (2015) C1

Download (201)

View PDF (237)

Neisseria gonorrhoeae Antimicrobial Resistance Surveillance: Consolidated Guidance

World Health Organization WHO (2020) C_WHO

Prevention, early diagnosis, and effective treatment are essential for the control and elimination of Neisseria gonorrhoeae as a public health problem. Currently, in Latin America and the Caribbean, treatment for gonorrhea infection is largely empiric and based on clinical diagnosis. In the Americas... more

Download (53)

View PDF (219)

Burnout Syndrome amongst Medical Students in Cameroon: A Cross-Sectional Analysis of the Determinants in Preclinical and Clinical Students

Njim T., H. Makebe, L. Toukam, et. al. Hindawi Psychiatry Journal (2019) C1

Volume 2019, Article ID 4157574, 7 pages https://doi.org/10.1155/2019/4157574

Download (210)

View PDF (244)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (158)

View PDF (122)

Buruli ulcer : management of Mycobacterium ulcerans disease : a manual for health care providers

J. Buntine; Crofts, K. World Health Organization WHO (2001) CC

This manual is addressed to health care providers dealing with Mycobacterium ulcerans disease (Buruli ulcer). The manual aims to achieve a better understanding of the disease, its clinical presentation and its surgical management. The manual is aimed particularly at district health care providers. A... more

Download (249)

View PDF (205)

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended

World Health Organization WHO (2023) CC

Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected. Infection prevention and control (IP... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023 recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Infection prevention and control guideline for Ebola and Marburg disease, August 2023
recommended